# Tocilizumab in Refractory ASS-ILD

> **NCT07662265** · — · COMPLETED · sponsor: **Hu Yinan** · enrollment: 111 (actual)

## Conditions studied

- Antisynthetase Syndrome
- Tocilizumab

## Interventions

- **DRUG:** Tociliuzumab

## Key facts

- **NCT ID:** NCT07662265
- **Lead sponsor:** Hu Yinan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662265, "Tocilizumab in Refractory ASS-ILD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*